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Abstract: Antimony toxicity occurs either due to occupational exposure or during therapy. 
Occupational exposure may cause respiratory irritation, pneumoconiosis, antimony spots 
on  the  skin  and  gastrointestinal  symptoms.  In  addition  antimony  trioxide  is  possibly 
carcinogenic to humans. Improvements in working conditions have remarkably decreased 
the incidence of antimony toxicity in the workplace. As a therapeutic, antimony has been 
mostly used for the treatment of leishmaniasis and schistosomiasis. The major toxic side-
effects  of  antimonials  as  a  result  of  therapy  are  cardiotoxicity  (~9%  of  patients)  and 
pancreatitis,  which  is  seen  commonly  in  HIV  and  visceral  leishmaniasis  co-infections. 
Quality control of each batch of drugs produced and regular monitoring for toxicity is 
required when antimonials are used therapeutically. 
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1. Introduction 
Antimony (symbol Sb from the latin stibium) is a silvery white metal with atomic number 51, that is 
found in the earth’s crust. Its main applications are industrial. Elemental antimony can be used for 
producing semiconductors,  infrared detectors and diodes. Because  of its relative inflexibility, it is 
usually mixed into alloys for further application, e.g., manufacture of lead storage batteries, solder, 
sheet and pipe metal, bearings, castings and pewter, etc. Antimony oxide can be used in fire-retardant 
formulations for plastics, rubbers, textiles, paper and paints whereas antimony trisulfide is used in the 
production of explosives, pigments, antimony salts and ruby glass [1-3]. Antimony compounds have 
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been  used  as  medicines  since  their  introduction  by  the  alchemist  John  of  Rupescissa  in  the  14th 
century [4], mainly in the treatment of two parasitic diseases, leishmaniasis and schistosomiasis.  
Antimony and its compounds are naturally present in the Earth’s crust and are released into the 
environment by natural discharges such as windblown dust, volcanic eruptions, sea spray, forest fires, 
and biogenic sources. The concentration of antimony in air ranges from a nanogram per cubic meter 
(ng/m
3) to about 170 ng/m
3. The concentration of antimony that is found dissolved in rivers and lakes 
is usually less than 5 parts of antimony in 1 billion parts of water (ppb) and it is found attached to 
particles of dirt. Antimony occurs predominantly in the pentavalent state in aerobic fresh water and sea 
water  and  the  trivalent  state  is  more  common  under  anaerobic  conditions  as  well  as  a  results  of 
anthropogenic activities. A U.S. geological survey showed that soil concentrations range from less 
than 1 to 8.8 ppm, with a mean of 0.48 ppm [5]. The average intake of antimony from food and water 
was estimated to be roughly 5 μg/day in a study [6]. These data show that the general population is 
exposed to low levels of antimony. Toxicity may arise during occupational exposure, domestic use or 
when  it  is  used  as  a  therapy.  This  review  discusses  antimony  toxicity  arising  from  occupational 
exposure and when it is used as a therapy. 
2. Results and Discussion  
2.1. Antimony as an Occupational Hazard 
Occupational  exposure  to  antimony  occurs  mainly  in  workers  involved  in  industries  producing 
antimony and antimony trioxide, metal mining, smelting and refining, coal-fired power plants, refuse 
incineration, or those working in indoor firing ranges. Most of the data of antimony toxicity comes 
from the time when primitive work conditions prevailed and there was no adequate protection for the 
workers. Another problem in assessing its toxicity industrially is that arsenic and lead are often found 
with it, and other toxic materials may also be produced in the course of the process, and separation of 
exposures may be difficult or impossible. 
2.1.1. Inhalational Exposure 
Health effects have been observed following inhalational exposure to several antimony compounds 
e.g., antimony trioxide, stibine (antimony hydride), antimony trisulfide, antimony pentoxide, antimony 
trichloride,  antimony  pentasulfide,  metallic  antimony,  etc.  The  absorption  of  antimony  from  the 
respiratory  tract  is  a  function  of  particle  size.  Aerosols  containing  small  particles  composed  of 
antimony compounds with low water solubility (e.g., particles of antimony oxides) are retained in the 
lungs for a longer period of time than those containing larger particles with high water solubility  
(e.g., particles of antimony tartrate) [7,8].  
2.1.1.1. Respiratory Effects 
Chronic exposure to antimony trioxide and/or pentoxide dust (8.87 mg antimony/m
3 or greater) was 
seen  to  cause  pneumoconiosis,  however,  these  workers  were  also  exposed  to  a  variety  of  other 
compounds like arsenic oxide, iron oxide, hydrogen sulfide, and sodium hydroxide [9,10]. Antimony 
pneumoconiosis was also described by Karajovic in a population of antimony miners and smelters in Int. J. Environ. Res. Public Health 2010, 7                 
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Yugoslavia  based  on  diffuse  x-ray  opacities  but  this  was  also  confounded  by  simultaneous  
silicosis  [11].  Other  respiratory  effects  reported  in  workers  include  chronic  bronchitis,  chronic 
emphysema,  inactive  tuberculosis,  pleural  adhesions,  and  respiratory  irritation  (characterized  by 
chronic  coughing,  wheezing  and  upper  airway  inflammation)  [10].  Similar  findings  were  seen  in 
animal studies [12].  
2.1.1.2. Cardiovascular Effects 
Cardiovascular  effects  in  humans  are  supported  by  the  finding  of  cardiac  effects  following 
parenteral  administration  of  antimony  to  humans.  Increased  blood  pressure  and  altered  ECG 
(electrocardiography) readings mostly of the T-waves were observed in workers exposed to 2.15 mg 
antimony/m
3 as antimony trisulfide for 8 months to 2 years; however these workers had also been 
exposed to phenol formaldehyde resin. Inhalation exposure to antimony trisulfide dust was also seen to 
result in degenerative changes in the myocardium and related ECG abnormalities in variety of animal 
species  [13].  Nevertheless,  evidence  of  heart  disease  from  industrial  exposure  to  antimony  is  not  
very strong. 
2.1.1.3. Gastrointestinal Effects 
Repeated prolonged exposure to airborne antimony trichloride  [14], antimony trisulfide  [13] or 
antimony  oxide  [15]  was  seen  to  cause  abdominal  pain,  diarrhea,  vomiting,  and  ulcers.  A  causal 
relationship to antimony exposure has not been definitely established because workers were exposed to 
a variety of other agents in addition to antimony that might cause or contribute to gastrointestinal 
effects (e.g., hydrogen chloride, sodium hydroxide). 
2.1.1.4. Dermal effects 
Airborne  antimony  has  effects  in  skin  described  as  “antimony  spots”  which  are  pustules  and 
eruptions in the trunk and limbs near sweat and sebaceous glands. This dermatitis is more commonly 
seen  in  association  with  hot  weather  and  in  workers  exposed  to  high  temperatures  [10,16,17]. 
Transferring the worker to a cooler environment often resulted in the rash clearing up within 3–14 days. 
2.1.1.5. Reproductive Effects 
Two thirds of rats exposed to 209 mg antimony/m
3 as antimony trioxide for 63 days failed to 
conceive. An increased incidence of spontaneous abortions and disturbances in menstruation, were 
reported in women working at an antimony metallurgical plant as compared to a control group. The 
women  were  exposed  to  a  mixture  of  antimony  trioxide,  antimony  pentasulfide,  and  metallic  
antimony [18]. 
2.1.1.6. Carcinogenicity 
There is inadequate evidence for carcinogenicity of antimony trioxide and trisulphide in humans but 
antimony trioxide and antimony trisulfide have been seen to cause lung tumours in rats. Antimony Int. J. Environ. Res. Public Health 2010, 7                 
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trioxide is classified as possibly carcinogenic to humans (Group 2B) by the International Agency for 
Research on Cancer [3].  
2.1.1.7. Genotoxicity 
The results of in vitro genotoxicity studies have shown positive results for chromosome breakage in 
human leukocytes [19]. In a study to assess genotoxic risk and oxidative damage in workers exposed 
to antimony trioxide, there was no difference in sister chromatid exchange and micronuclei between 
those exposed and controls however, increased oxidative damage to DNA was observed in the exposed 
group  [20].  In  a  recent  study,  antimony  showed  genotoxicity  in  both  bacterial  mutation tests  and 
chromosomal  aberration  tests  in  cultured  mammalian  cells  [21].  Due  to  lack  of  in  vivo  studies 
genotoxicity in humans cannot be determined at this time. 
2.1.2. Oral Exposure 
Historically, antimony has been known for its emetic properties. Amounts as low as 0.529 mg/kg 
can result in vomiting. Oral exposure to antimony predominantly affects the gastrointestinal system. 
Seventy  people  became  acutely  ill  after  drinking  lemonade  containing  0.013%  antimony.  The 
lemonade  had  been  prepared  and  left  overnight  in  buckets  coated  with  enamel  containing  2.88% 
antimony  trioxide.  Fifty-six  people  were  taken  to  the  hospital  with  burning  stomach  pains,  colic, 
nausea and vomiting. Most recovered within 3 hours, but in some cases recovery was not complete for 
several days [22]. It is estimated that a person consuming 300 mL of lemonade would have received a 
dose of approximately 36 mg antimony, or approximately 0.5 mg/kg for a 70-kg adult. No other 
toxicity has been recorded in humans for oral exposure to antimony.  
2.1.3. Other Exposure from Antimony Compounds 
Antimony was implicated in the cause of cot deaths, or Sudden Infant Death Syndrome (SIDS) by 
Richardson in 1990 [23]. It was claimed that antimony compounds used in fireproofing cot furnishings 
amongst  other  additives  was  primarily  responsible  for  SIDS  due  to  the  action  of  a  fungus 
(Scopulariopsis brevicaulis) growing on polyvinyl chloride cot mattress covers. In vitro experiments 
appeared to demonstrate the release of stibine and phosphine, hydrides of antimony oxide fire retardant 
and phosphorus plasticisers from polyvinyl chloride mattress covers which had been treated with these 
substances  and  it  was  claimed  that  they  had  caused  deaths  from  their  toxicity.  However,  urine 
antimony  concentration  of  antimony  in  infants  dying  from  SIDS  were  similar  to  values  found  in 
control infants and healthy infants [24]. This causal role of antimony in SIDS was ultimately refuted 
due to lack of evidence. 
Recently the National Institute for Occupational Safety and Health investigated a possible outbreak 
of antimony toxicity wherein 30 firefighters reported elevated antimony levels on hair analyses as 
some  fire  fighter  station  uniforms  contain  the  flame-retardant  antimony  trioxide.  However,  no 
differences in urine antimony levels between departments wearing and not wearing this uniform were 
detected. It was hence concluded that wearing antimony-containing uniforms does not pose a risk for 
antimony toxicity [25]. The CDC stated in their report that only validated methods should be used for Int. J. Environ. Res. Public Health 2010, 7                 
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the determination of antimony toxicity. Urine testing is the most accurate, reliable, and valid test 
method for measuring antimony levels in the body. CDC has established ranges for urine levels of 
antimony  in  the  U.S.  population:  0.120–0.364  micrograms/gram  creatinine.  Hair  testing  is  not  a 
validated method for heavy metals testing (which includes antimony), and is not recommended [26]. 
2.1.4. Prevention of Exposure to Antimony 
To  safeguard  the  general  public  in  USA,  the  Environmental  Protection  Agency  (EPA)  allows  
0.006 parts of antimony per million parts of drinking water [27]. In the guidelines for Drinking-water 
Quality, WHO established a tolerable daily intake (TDI) of 6 μg/kg bodyweight/day for antimony [28].  
The  EPA  requires  that  discharges  or  spills  into  the  environment  of  5,000  pounds  or  more  of 
antimony  be  reported.  The  Occupational  Safety  and  Health  Administration  (OSHA)  has  set  an 
occupational exposure limit of 0.5 milligrams of antimony per cubic meter of air (0.5 mg/m³ ) for an  
8-hour workday, 40-hour workweek [5].  
2.2. Antimony in Therapeutics 
Antimony had a reputation of being a universal panacea of all kinds of diseases in the middle ages. 
In  1631,  the  German  alchemist  Adrian  Von  Mynsicht  successfully  described  potassium  antimony 
tartrate [29]. Since the last century antimonials have been used for the treatment of two parasitic 
diseases schistosomiasis and leishmaniasis. 
2.2.1. Schistosomiasis  
A number of antimony compounds have been used for the treatment of schistosomiasis e.g., sodium 
antimony  tartrate,  sodium  antimony  dimercaptosuccinate  (stibocaptate,  Astiban)  sodium  antimonyl 
gluconate,  etc.  [30,31].  In  a  comparative  trial  of  three  antimonials  used  in  schistosomiasis,  78% 
patients had gastrointestinal symptoms e.g., vomiting, anorexia. Arthralgia was common in all the 
three groups, but severity of the symptoms were more in patients taking antimony sodium tartrate 
(AST) and sodium antimonyl gluconate (TSAG). Complete flattening or frank inversion of T waves in 
ECG was seen in 68%, 67% and 42% of TSAG, AST and TWSb (antimony dimercaptosuccinate) 
respectively. Although substernal pain was common only three cases on i.v. sodium antimony tartrate 
had an acute vascular collapse. Cough was a common symptom however pneumonia occurred in two 
patients  and  hepatotoxicity  was  observed  in  1.9%  patients  [31].  With  the  advent  of  the  more 
efficacious and less toxic alternative praziquantel, the trivalent antimonials were phased out from the 
treatment of schistosomiasis in the 1970s. 
2.2.2. Leishmaniasis 
In  1912,  Vianna  successfully  used  tartar  emetic  to  cure  cutaneous  leishmaniasis  for  the  first  
time [32]. In 1915 it was used for visceral leishmaniasis for the first time. Tartar emetic, although 
extremely effective in the treatment of leishmaniasis, was abandoned due to its toxicity. Injections led 
to  severe  vomiting  and  retching,  apart  from  that  pneumonia,  joint  pain,  lung,  kidney  and  bowel 
complication was also reported [33]. In 1923 the first pentavalent antimony compound urea stibamine Int. J. Environ. Res. Public Health 2010, 7                 
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was discovered which had much less toxicity than its trivalent predecessor. Later it was replaced by 
sodium  stibogluconate  which  to  date  remains  the  drug  of  choice  for  the  treatment  of  visceral 
leishmaniasis worldwide, except in North Bihar where a high level of antimony resistance exists. 
Treatment with sodium antimony gluconate at the therapeutic dose may result in minor side effects 
such  as  arthralgia,  myalgia,  transient  elevation  of  hepatocellular  enzyme  levels,  and  minor  ECG  
changes [34,35]. A decrease in the height of T waves and T-wave inversion is seen in about 50% of 
patients [35]. Although serious cardiotoxicity is uncommon, occurring in less than 9% cases, death 
may result in these patients [34,36-38]. Features of dangerous cardiotoxicity include a concave ST 
segment and prolongation of the corrected QT interval (QTc), which is measured by dividing the QT 
interval by the square root of the preceding interval between the preceding two QRS complexes (RR 
interval) [39]. Normal QTc values are less than 0.37 s and 0.44 s for males and females, respectively, 
while an increase of 0.03 s or an absolute value of greater than 0.50 s are considered ominous [34,35]. 
In a cluster of cases with cardiotoxicity due to sodium antimony gluconate, the first dangerous sign 
of  cardiotoxicity  was  prolonged  QTc,  followed  by  multiple  ventricular  ectopics,  then  ventricular 
tachycardia,  torsade  de  pointes,  ventricular  fibrillation,  and  potentially  death.  In  this  series 
cardiotoxicity occurred at a much lower cumulative dose than previously reported and was associated 
with higher osmolarity of the batch of drugs. Elevated osmolarity reflects an increased concentration 
of particles, and thus reflect both the concentration of the drug and its state of aggregation. However, 
in this study implicated lot had comparable antimony contents as the effective lot, implying some other 
cause for the increase in their osmolarity. Incorrect formulation e.g., incorrect antimony to gluconate 
ratio and the presence of trivalent antimony in a preparation could also result in increased osmolarity, 
This study suggests that higher than expected osmolarity may serve as a nonspecific indicator of a 
problem  in  formulation  [40]. Another  outbreak  of  fatal  cardiotoxicity  occurred  in  Nepal  amongst 
visceral  leishmaniasis  patients  treated  with  a  recently  introduced  batch  of  generic  sodium 
stibogluconate. Eight (36%) of 23 patients treated with this batch died, and  five deaths (23%) were 
attributed to the cardiotoxicity of the drug [41]. 
The exact mechanism for cardiotoxicity is not known, but antimonials prolong the action potential 
of  guinea  pig  ventricular  myocytes  at  therapeutically  relevant  concentrations  for  the  treatment  of 
leishmaniasis via an increase in cardiac calcium currents. In the heart, calcium currents regulate the 
plateau phase of the cardiac action potential and increased amplitudes produce a delay in cardiac 
repolarization, which may explain the propensity of patients treated with antimonial compounds to 
develop QT prolongation and life-threatening arrhythmias [42]. It is now generally accepted that all 
pentavalent antimonials are prodrugs that require biological reduction to the trivalent form [Sb(III)] for 
antileishmanial activity. The site (amastigote or macrophage) and mechanism of reduction (enzymatic 
or nonenzymatic) remain controversial [43]. Although the exact molecular mechanism(s) underlying 
the increase in calcium currents observed with trivalent antimony is not known, it is postulated that 
high affinity for sulfhydryl groups may affect calcium channels by oxidizing cysteine residues located 
either directly on the channel protein or on a closely associated protein [44]. 
Pancreatitis is another adverse effect of pentavalent antimonials. Incidence of all adverse events and 
especially of pancreatitis is quite high in HIV and VL coinfection. In a study of 25 HIV-VL coinfected 
patients,  adverse  effects  were  observed  in  56%.  In  seven  (28%),  treatment  with  meglumine 
antimoniate (MA) was discontinued permanently due to serious adverse effects that included acute Int. J. Environ. Res. Public Health 2010, 7                 
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pancreatitis (5), acute renal failure (1), and leukopenia (1). Three (12%) patients died during therapy 
due to severe acute pancreatitis attributable to MA. Patients who developed acute pancreatitis were not 
alcohol  drinkers,  their  triglyceride  levels  were  not  elevated  and  the  biliary  tree  was  normal  on 
abdominal ultrasound examination [45]. The reasons behind increased pancreatitis in these patients 
could be multiple. Amount of antimony has been seen to vary with different batches which could lead 
to use of higher doses of Sb
V than intended [46]. Subclinical pancreatitis frequently occurs in patients 
with AIDS which could predispose them to pancreatic disease [47,48]. Elevation of pancreatic and 
liver  enzymes  were  also  observed  in  a  study  of  new  world  cutaneous  leishmaniasis  in  which 
pentavaalent antimonials were given at the dose of 20 mg/kg/day for 20 days. The most prominent 
complaints,  myalgia  and  abdominal
  pain,  were  reported  by  29–56%  and  4–25%  of  the  patients,
 
respectively. Another 46–69% had
 mild-to-moderate elevations and 2–19% had grade 3 elevations of 
pancreatic  enzymes,  whereas,  44–75%  had  mild-to-moderate  elevations
  and  4–12%  had  grade  3 
elevations of liver enzymes [49].  
In  Brazil  higher  frequency  of  skin  reactions  was  observed  in  some  patients  of  cutaneous 
leishmaniasis treated with meglumine antimoniate. This lot of drugs had lower pH and osmolarity and 
higher concentrations of total and trivalent antimony, lead, cadmium and arsenic and the skin reaction 
was attributed to the heavy metal contamination [50]. 
3. Conclusions 
With dramatic improvements in working conditions in antimony processing and stringent guidelines 
antimony has largely ceased to be a common occupational health hazard, however, constant vigilance 
is required for emerging toxicity. 
As for its use as a therapeutic agent, continuous quality control of each batch of drugs produced 
should be done to ensure safety. The simple technique of measuring of osmolarity may help identify 
inappropriately manufactured drugs. Regular monitoring for toxicity needs to be done. Use of alternate 
less toxic drugs for the treatment of leishmaniasis especially in HIV co-infected patients could be 
another strategy. Availability of drugs like miltefosine, paramomycin and liposomal Amphotericin B 
(L-AmB)  makes  this  a  viable  option.  Moreover,  a  preferential  pricing  agreement  with  WHO 
(agreement between Gilead and WHO of 14 March 2007) has recently reduced the price of L-AmB 
(AmBisome®) for endemic regions to $20 per 50-mg vial [51]. This preferential pricing further opens 
the prospect of either single dose treatment or short course combination regimens. Combining multiple 
drugs not only reduces toxicity of individual drugs but also reduces drug pressure, decreases duration 
of  treatment  leading  to  better  compliance,  decreased  hospital  stay  and  ultimately  cost  of  therapy. 
Paromomycin  was  one  of  the  first  drug  to  be  used  in  combination  with  pentavalent  antimony 
compounds in the 1990s in Kenya, India and Sudan [52-54]. This combination is currently in use in 
Sudan [55]. Well conducted trials of combination therapy are the need of the hour to increase efficacy, 
decrease toxicity and prevent resistance.  
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